$1.17 -0.04 (-3.306%) Peregrine Pharmaceuticals Inc - NASDAQ

Sep. 3, 2015 | 04:00 PM

Insider Transactions

Latest insider trade data based on US Insider Regulatory Filings which are subject to input errors by filers. Insiderslab.com may adjust certain filings for common filing errors on a reasonable effort basis.
Date Name Title Volume Trade Price Holding Change
4/30/2015Fussey Shelley PMV.P., Intellectual Property7,179$1.118.53%
4/30/2015KING STEVEN WPresident & CEO4,634$1.112.68%
4/30/2015LYTLE PAUL JChief Financial Officer5,217$1.115.14%
10/31/2014KING STEVEN WPresident & CEO3,280$1.361.93%
10/31/2014Fussey Shelley PMV.P., Intellectual Property5,362$1.366.80%
4/30/2014Fussey Shelley PMV.P., Intellectual Property6,571$1.119.10%
4/30/2014KING STEVEN WPresident & CEO4,020$1.112.42%
10/31/2013Fussey Shelley PMV.P., Intellectual Property6,752$1.0810.31%
10/31/2013KING STEVEN WPresident & CEO4,131$1.082.20%
4/30/2013LYTLE PAUL JChief Financial Officer11,988$0.7113.39%
4/30/2013KING STEVEN WPresident & CEO6,516$0.718.06%
4/30/2013Fussey Shelley PMV.P., Intellectual Property10,481$0.7119.06%
10/31/2012KING STEVEN WPresident & CEO11,000$0.3915.74%
10/31/2012Fussey Shelley PMV.P., Intellectual Property17,980$0.3948.57%
10/31/2012LYTLE PAUL JChief Financial Officer20,885$0.3930.44%
4/30/2012LYTLE PAUL JChief Financial Officer12,498$0.4022.27%
4/30/2012KING STEVEN WPresident & CEO10,726$0.4018.13%
4/30/2012Fussey Shelley PMV.P., Intellectual Property12,498$0.4050.97%
3/14/2012SWARTZ ERIC SDirector16,000$0.6214.55%
10/31/2011KING STEVEN WPresident & CEO4,804$0.898.84%
10/31/2011LYTLE PAUL JChief Financial Officer5,122$0.8910.04%
10/31/2011Fussey Shelley PMV.P., Intellectual Property5,122$0.8926.40%
4/29/2011KING STEVEN WPresident & CEO3,046$1.283.26%
4/29/2011Fussey Shelley PMV.P., Intellectual Property5,371$1.2818.50%
4/29/2011LYTLE PAUL JChief Financial Officer5,947$1.288.25%
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (PPHM), click here.
Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!